Heuck A, Mattke S, Seemann M, Müller D, Beuers U, Huber A, Reiser M
Institut für Radiologische Diagnostik, Klinikum Grosshadern, Ludwig-Maximilians-Universität München.
Rofo. 1997 Jan;166(1):14-7. doi: 10.1055/s-2007-1015370.
To assess whether the hepatic density on CT scans of patients receiving amiodarone therapy differs significantly from the hepatic density of a control group not receiving the drug.
Hepatic density was assessed by CT in 31 patients receiving amiodarone, 7 receiving short-term (12-14 days), 8 receiving mid-term (20-89 days) and 16 receiving long-term therapy (3-26 months), as well as in a control group of 15 patients.
Mean liver density of all patients under amiodarone therapy (77.9 +/- 11.7 HU) was significantly higher (p < 0.005) than in the control group (56.6 +/- 2.8 HU). The smallest increase in density was found in patients with short-term therapy (64.8 +/- 3.4 HU; p < 0.05), the greatest increase in patients with long-term therapy (85.0 +/- 8.9 HU; p < 0.001).
In patients receiving amiodarone therapy, a significantly increased hepatic density on CT scans is observed. This finding has to be considered as a differential diagnosis to other hepatopathies with increased density of the liver.
评估接受胺碘酮治疗的患者CT扫描中的肝脏密度与未接受该药物治疗的对照组肝脏密度是否存在显著差异。
对31例接受胺碘酮治疗的患者进行CT检查评估肝脏密度，其中7例接受短期（12 - 14天）治疗，8例接受中期（20 - 89天）治疗，16例接受长期治疗（3 - 26个月），同时对15例患者组成的对照组进行同样检查。
所有接受胺碘酮治疗患者的肝脏平均密度（77.9±11.7HU）显著高于对照组（56.6±2.8HU，p < 0.005）。短期治疗患者的密度增加最小（64.8±3.4HU；p < 0.05），长期治疗患者的密度增加最大（85.0±8.9HU；p < 0.001）。
在接受胺碘酮治疗的患者中，CT扫描显示肝脏密度显著增加。这一发现必须作为肝脏密度增加的其他肝病的鉴别诊断依据。
